Opendata, web and dolomites

MATURE-NK SIGNED

MAnufacturing of TUmour-REactive Natural Killer cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MATURE-NK project word cloud

Explore the words cloud of the MATURE-NK project. It provides you a very rough idea of what is the project "MATURE-NK" about.

humanized    modules    cross    intellectual    combine    cell    experts    companies    bispecifc    inhibitory    sectors    bridge    blocking    immunotechnology    student    antibody    basic    bioinformatics    ligand    classified    checkpoint    killer    medicine    personalized    translate    groups    private    winter    genetically    ligands    pioneering    models    first    link    therapeutic    comprise    training    competences    business    evaluation    car    manipulated    portfolios    donor    network    atmps    nk    chimeric    clinical    industry    oriented    gap    biotech    natural    recipient    protocol    exchange    trial    combination    fortify    diseases    activating    inhibitors    trials    receptors    modulation    cells    unknown    interactions    designed    reactivity    manufacturing    antigen    property    compliant    therapies    summer    anti    refractory    activated    train    translational    therapy    biology    incurable    modification    medicinal    mouse    tumor    treatment    gmp    building    schools    reagents    cancer    rights    receptor   

Project "MATURE-NK" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE HOCHSCHULE HANNOVER 

Organization address
address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625
website: www.mh-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙351˙662 €
 EC max contribution 3˙351˙662 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 249˙216.00
2    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 286˙275.00
3    UNIVERSITAT BASEL CH (BASEL) participant 265˙226.00
4    INNATE PHARMA FR (MARSEILLE) participant 262˙875.00
5    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 262˙875.00
6    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) participant 260˙300.00
7    IRCCS OSPEDALE POLICLINICO SAN MARTINO IT (GENOVA) participant 258˙061.00
8    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 255˙934.00
9    GLYCOSTEM-THERAPEUTICS B.V. NL (OSS) participant 255˙374.00
10    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 249˙216.00
11    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 249˙216.00
12    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 249˙216.00
13    UNIVERSIDAD POMPEU FABRA ES (BARCELONA) participant 247˙872.00

Map

 Project objective

'This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases. This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products ('ATMPs'), and their use in treatment of cancer refractory to classical therapies. For this we combine experts in NK cell biology supported by bioinformatics, clinical groups pioneering NK cell therapies and biotech companies with NK cell-based portfolios. A student exchange will ensure training in basic, clinical and private sectors. Network-wide training modules organized in summer/winter schools include immunotechnology, business management and intellectual property rights. This will train competences important to translate research findings to personalized medicine. In research we build on information from clinical trials of NK cell-based therapies. We will improve anti-tumor reactivity of NK cells including selection of NK subsets and modulation of NK receptor/ligand interactions. First, this will comprise i) improved donor/recipient combination and NK subsets and ii) modification of NK cells by chimeric antigen receptors ('CAR') and bispecifc antibody reagents to cross-link NK cells to tumor targets. Second, it will fortify NK cell reactivity by i) blocking ligand interactions of inhibitory receptors ('checkpoint inhibitors') and ii) defining unknown ligands of activating NK receptors on tumor cells. Third, procedures and NK products in their best combination will be developed by i) evaluation in humanized mouse models, ii) building a GMP-compliant manufacturing process and iii) design of a clinical trial protocol. The project should provide for manufacturing of NK cell-based therapeutic products and their evaluation in clinical trials. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MATURE-NK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MATURE-NK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

i-CONN (2019)

Interdisciplinary connectivity: Understanding and managing complex systems using connectivity science

Read More  

MoSaiQC (2020)

Modular Systems for Advanced Integrated Quantum Clocks

Read More  

Shape-IT (2019)

Supporting the interaction of Humans and Automated vehicles: Preparing for the EnvIronment of Tomorrow

Read More